Clinical Developments in Inflammatory Arthritis 2017

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Psoriasis Treatments

Psoriatic Arthritis.

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

Treatment Algorithms in Melanoma: Past, Present, and Future

Improving Survival in Glioblastoma Multiforme

Relapsed/Refractory Follicular Lymphoma Conundrums

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Updates on Emerging GLP-1 Receptor Agonists

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Diagnosing Rheumatoid Arthritis Early

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

From Conference to Practice: Big Data in Psoriasis

Mid-Year Hemophilia Update

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Novel Small Molecule Therapies in Rheumatoid Arthritis

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Clinical Updates in RA: New Developments and Insights From Washington

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Evolving Treatment Landscape for PsA

Biotherapeutics.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Rheumatoid Arthritis Management

Getting to Grips With the Science of CGRP and Migraine

What's New in Therapeutic Options for Moderate to Severe RA?

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Patient Questions and Expert Answers in Psoriasis:

Updates in RA, PsA, and Biosimilars

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Understanding How IL-23p19 Inhibitors Work in Psoriasis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Nat. Rev. Rheumatol. doi: /nrrheum

Rheumatoid Arthritis.

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

Immune Checkpoint Inhibitors in Lung Cancer

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Treatment Advances for RA

Psoriatic Arthritis.

Presentation transcript:

Clinical Developments in Inflammatory Arthritis 2017

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction Psoriatic Arthritis

Treatment of Psoriatic Arthritis The Pathophysiologic Cascade

Treating and Managing Psoriatic Arthritis

Introduction to Rheumatoid Arthritis

Management of RA With DMARDs

Updates on JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Long-Term Safety of Baricitinib for the Treatment of RA (5.5 Years)

Pain Control With Baricitinib and Methotrexate in DMARD-Naive Patients

Safety and Efficacy of Tofacitinib ORAL Strategy

Upadacitinib in Patients With Inadequate Response to csDMARDs

Upadacitinib in Patients With Inadequate Response or Intolerance to Biological DMARDs

What's New in Therapies for Rheumatoid Arthritis?

Impact of Adalimumab on Prednisone Use

CV Safety of Tocilizumab vs Abatacept in Patients With RA

Sustained Response After Discontinuation of MTX in Patients Treated With SC Tocilizumab

Sustained Response After Discontinuation of MTX in Patients Treated With SC Tocilizumab (cont)

Discontinuation of MTX for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination

Updates on Treatments in Psoriatic Arthritis

Efficacy and Safety of Abatacept Results From the ASTRAEA Study

Radiographic Progression of Structural Joint Damage With Ixekizumab in SPIRIT-P1

Efficacy and Safety of Ixekizumab in Patients With Inadequate Response to TNFi: SPIRIT-P2

Safety and Efficacy of Guselkumab Phase 2a RCT (24 Week and 56 Week)

Monitoring Disease Activity in PsA

Treatment and Management of PsA

What's New in Therapies for PsA?

Inhibition of Radiographic Progression in Active PsA by Adalimumab

Efficacy and Safety of Golimumab at Week 24 GO-VIBRANT Study

Inhibition of Radiographic Progression by SC Secukinumab

OPAL BROADEN Use of Tofacitinib in Patients With PsA

OPAL BEYOND Use of Tofacitinib in Patients With PsA

Apremilast Monotherapy in Biologic-Naive Patients With Active PsA: ACTIVE Trial

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)